A-Skin secures patent for groundbreaking skin engineering therapy
WHF therapy can be directly applied on a wound to stimulate the natural human wound healing process.
A-Skin has secured an important patent for its groundbreaking Wound Healing Formulation (WHF) therapy. The worldwide market for this indication is estimated at $20.5 billion by 2020. Furthermore, A-Skin’s lead product Tiscover is ready to enter a clinical phase II trial after finalization of an ongoing financing round to raise €7,5 million.
WHF is a substance that can be directly applied on a wound to stimulate the wound healing. WHF consists of wound healing factors secreted by cultured immortalized human skin cells, with the potential to vitalize the natural human wound healing process. WHF substance can be applied directly on the wound bed in a gel, blister, bandage etc. The target population is everyone with a small simple skin wound that needs wound healing stimulation. WHF is classified as a Non-Cell Based Medicinal Product at the EMA.
Prof. dr. Rik J. Scheper, A-Skin’s CEO, comments: "Securing the IP of WHF means a very important milestone for our company, with now two ground breaking skin engineering products in our pipeline. Both WHF and Tiscover tap into a huge worldwide market for regenerative skin engineering medicine and non-healing chronic wound treatment. Some 50 million patients around the globe suffer from non-healing wounds following higher incidence of diabetes, ageing and growing immobilization. Therefore our solutions have a large societal impact by healing patients wounds, taking away the pain and giving back their self-esteem.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance